CTOs on the Move


 
Color`s mission is to help people lead the healthiest lives that science and medicine can offer. We launched in April 2015 with a simple, affordable genetic test to help people understand their risk for hereditary cancer. In 2017, we added coverage for hereditary heart conditions.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.color.com
  • 831 Mitten Rd
    Burlingame, CA USA 94010
  • Phone: N/A

Executives

Name Title Contact Details
Coe Salzgeber
Senior Director, Data & Infrastructure Profile
Lisa Hall
Chief Information Security Officer Profile

Funding

Color raised $75M on 01/14/2020
Color raised $167M on 01/04/2021
Color raised $100M on 11/09/2021

Similar Companies

Biomet Microfixation

Founded by Walter Lorenz more than thirty years ago, Biomet Microfixation manufactures a complete range of craniomaxillofacial products, including LactoSorb, the first completely resorbable fixation system available in the U.S. Other products include

HiFiBiO - High Fidelity Biology

HiFiBiO SAS commercializes proprietary single cell technologies for applications in drug and biomarker discovery and development.

Innovative Biosensors

Innovative Biosensors is a Derwood, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kinnate

Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine.

Aspira Women`s Health

Aspira Women`s Health Inc. (formerly known as Vermillion, Inc. Nasdaq: VRML) is transforming women`s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1®plus combines our FDA-cleared products OVA1® and OVERA® to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and a more comprehensive genetic testing options with a gynecologic focus. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.